Former OpenAI science lead launches Warp Sciences with $215M to automate wet labs

Kevin Weil, who served as OpenAI's science lead, has unveiled Warp Sciences, a startup that applies AI and robotics to the physical labor of drug discovery. According to TechCrunch, the company has raised $215 million at an $865 million valuation, figures Weil shared in an announcement posted on X. Lightspeed led the financing, with IVP, Premji Invest and Lux Capital also taking part. (TechCrunch's headline renders the name as Warp Science, while its story text consistently uses Warp Sciences.)

Teaching robots the bench work

The startup's focus is the wet lab: the benches, glassware and instruments where potential medicines are actually synthesized and assayed. Its robots are meant to produce and evaluate the many variations of a molecule that scientists flag as promising, work that is slow, repetitive and, at scale, extremely labor-intensive.

Rather than programming the machines directly, Warp Sciences plans to have its human chemists teach by example. TechCrunch reports that these chemists wear camera rigs and sensor-lined gloves as they carry out procedures, capturing the fine-grained motion data the robots need to reproduce the same tasks. Once trained, the machines can keep working day and night without shift changes, which the company expects to shorten discovery timelines.

The reshoring angle

There is also a supply-chain argument behind the company. As TechCrunch notes, biotechs have spent years handing the bulk synthesis of thousands of molecular variants to Chinese contract organizations such as WuXi AppTec. Weil wants to bring that work back onshore and reduce how exposed the drug development process is to geopolitical friction.

In that sense, the pitch is about industrial capacity as much as automation: if robotic labs can match offshore contractors on cost while running continuously, domestic drug pipelines gain a layer of protection from disruptions abroad.

Why it matters

The launch sits at the intersection of two larger shifts. One is the effort to push AI from generating text and code toward controlling physical equipment, with laboratories a natural proving ground because procedures are precise, measurable and repeatable. The other is the steady rethinking of globalized supply chains in strategically important industries, where biotech's reliance on Chinese manufacturing has drawn particular scrutiny.

The money is its own signal: a newly announced company commanding close to a billion-dollar valuation suggests investors see automated wet labs as core infrastructure for pharmaceutical research rather than a niche tool. Still, the announcement covers the launch and funding only. TechCrunch's report mentions no published results, customers or pharmaceutical partners, so whether robot-run chemistry can genuinely outperform the existing contract-research model on cost, speed and reliability remains to be demonstrated.